Astrazeneca Plc LSE
Stay in step with market opportunities and get insights, actionable trade ideas and dedicated support.
- Newest
- Popular
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q4 preview: Where next for the AstraZeneca share price?
Markets believe AstraZeneca can continue to deliver strong double-digit growth in 2022, but will the pharma giant’s outlook meet expectations this week?
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
Why trade with City Index?
Tight spreads from 0.5 pts on FX and 1 pt on indices.
Award-winning platforms with fast and secure execution.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
Open an account in minutes
Experience award-winning platforms with fast and secure execution, and enjoy tight spreads from 0.5 pts on FX and 1 pt on indices.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
AstraZeneca Q1 preview: Where next for AstraZeneca stock?
AstraZeneca’s results will benefit from the acquisition of Alexion, but questions remain over its Covid-19 drugs and the outlook in China.
From time to time, StoneX Financial Pty Ltd (“we”, “our”) website may contain links to other sites and/or resources provided by third parties. These links and/or resources are provided for your information only and we have no control over the contents of those materials, and in no way endorse their content. Any analysis, opinion, commentary or research-based material on our website is for information and educational purposes only and is not, in any circumstances, intended to be an offer, recommendation or solicitation to buy or sell. You should always seek independent advice as to your suitability to speculate in any related markets and your ability to assume the associated risks, if you are at all unsure. No representation or warranty is made, express or implied, that the materials on our website are complete or accurate. We are not under any obligation to update any such material.
As such, we (and/or our associated companies) will not be responsible or liable for any loss or damage incurred by you or any third party arising out of, or in connection with, any use of the information on our website (other than with regards to any duty or liability that we are unable to limit or exclude by law or under the applicable regulatory system) and any such liability is hereby expressly disclaimed.